ITI 214

Drug Profile

ITI 214

Alternative Names: IC-200214; ITI-214

Latest Information Update: 06 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Intra-Cellular Therapies
  • Class Antiparkinsonians; Nootropics; Small molecules
  • Mechanism of Action Type 1 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cognition disorders

Most Recent Events

  • 06 Mar 2017 ITI 214 is still in phase I trials for Cognition disorders in USA and Japan
  • 01 Mar 2017 Intra-Cellular Therapies plans a phase I/II trial in Parkinson's disease
  • 21 Sep 2015 Takeda completes a phase I bioavailability trial in Cognition disorders in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top